Search research articles
Contact Us
Filters
Showing results (141-150 of 150) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 150 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2019
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Razelle Kurzrock, Douglas W Ball, Marianna L Zahurak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M Schlumberger, R Elisei, S Müller, et al.
Biostatistics (Oxford, England)
|
August 20, 2003
Waiting for organ transplantation: results of an analysis by an Institute of Medicine Committee
Robert D Gibbons, Naihua Duan, David Meltzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Cabozantinib in progressive medullary thyroid cancer
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.
The Journal of Clinical Investigation
|
August 22, 2018
O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis
Kekoa Taparra, Hailun Wang, Reem Malek, et al.
Cancer Cell
|
January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Cancer Biology & Therapy
|
September 7, 2010
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
Alvarez Hector, Elizabeth A Montgomery, Collins Karikari, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 25, 2012
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS
Nishant Agrawal, Yuchen Jiao, Mark Sausen, et al.
Nature
|
February 28, 2020
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Zhihao Lu, Jianling Zou, Shuang Li, et al.
Cell Reports
|
February 27, 2024
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
Peter Y F Zeng, Stephenie D Prokopec, Stephen Y Lai, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 150) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 150 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2019
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Razelle Kurzrock, Douglas W Ball, Marianna L Zahurak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M Schlumberger, R Elisei, S Müller, et al.
Biostatistics (Oxford, England)
|
August 20, 2003
Waiting for organ transplantation: results of an analysis by an Institute of Medicine Committee
Robert D Gibbons, Naihua Duan, David Meltzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Cabozantinib in progressive medullary thyroid cancer
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.
The Journal of Clinical Investigation
|
August 22, 2018
O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis
Kekoa Taparra, Hailun Wang, Reem Malek, et al.
Cancer Cell
|
January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Cancer Biology & Therapy
|
September 7, 2010
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
Alvarez Hector, Elizabeth A Montgomery, Collins Karikari, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 25, 2012
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS
Nishant Agrawal, Yuchen Jiao, Mark Sausen, et al.
Nature
|
February 28, 2020
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Zhihao Lu, Jianling Zou, Shuang Li, et al.
Cell Reports
|
February 27, 2024
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
Peter Y F Zeng, Stephenie D Prokopec, Stephen Y Lai, et al.
Page
of 15